Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 22

1.

Reverse immunology: From peptide sequence to tumor-killing human T-cell clones.

Vanhaver C, Gordon-Alonso M, Bayard A, Catanese MT, Colau D, van der Bruggen P, Bruger AM.

Methods Enzymol. 2020;631:159-194. doi: 10.1016/bs.mie.2019.05.033. Epub 2019 Jun 17.

PMID:
31948546
2.

Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade.

D'Alise AM, Leoni G, Cotugno G, Troise F, Langone F, Fichera I, De Lucia M, Avalle L, Vitale R, Leuzzi A, Bignone V, Di Matteo E, Tucci FG, Poli V, Lahm A, Catanese MT, Folgori A, Colloca S, Nicosia A, Scarselli E.

Nat Commun. 2019 Jun 19;10(1):2688. doi: 10.1038/s41467-019-10594-2.

3.

Author Correction: The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry.

Doyle T, Moncorgé O, Bonaventure B, Pollpeter D, Lussignol M, Tauziet M, Apolonia L, Catanese MT, Goujon C, Malim MH.

Nat Microbiol. 2019 Mar;4(3):539. doi: 10.1038/s41564-019-0366-0.

PMID:
30670794
4.

Production and Purification of Cell Culture Hepatitis C Virus.

de la Fuente C, Catanese MT.

Methods Mol Biol. 2019;1911:105-119. doi: 10.1007/978-1-4939-8976-8_7.

PMID:
30593621
5.

The interferon-inducible isoform of NCOA7 inhibits endosome-mediated viral entry.

Doyle T, Moncorgé O, Bonaventure B, Pollpeter D, Lussignol M, Tauziet M, Apolonia L, Catanese MT, Goujon C, Malim MH.

Nat Microbiol. 2018 Dec;3(12):1369-1376. doi: 10.1038/s41564-018-0273-9. Epub 2018 Nov 26. Erratum in: Nat Microbiol. 2019 Mar;4(3):539.

6.

Immune Profiling of Premalignant Lesions in Patients With Lynch Syndrome.

Chang K, Taggart MW, Reyes-Uribe L, Borras E, Riquelme E, Barnett RM, Leoni G, San Lucas FA, Catanese MT, Mori F, Diodoro MG, You YN, Hawk ET, Roszik J, Scheet P, Kopetz S, Nicosia A, Scarselli E, Lynch PM, McAllister F, Vilar E.

JAMA Oncol. 2018 Aug 1;4(8):1085-1092. doi: 10.1001/jamaoncol.2018.1482.

7.

3D microfluidic liver cultures as a physiological preclinical tool for hepatitis B virus infection.

Ortega-Prieto AM, Skelton JK, Wai SN, Large E, Lussignol M, Vizcay-Barrena G, Hughes D, Fleck RA, Thursz M, Catanese MT, Dorner M.

Nat Commun. 2018 Feb 14;9(1):682. doi: 10.1038/s41467-018-02969-8.

8.

Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis.

Lussignol M, Kopp M, Molloy K, Vizcay-Barrena G, Fleck RA, Dorner M, Bell KL, Chait BT, Rice CM, Catanese MT.

Proc Natl Acad Sci U S A. 2016 Mar 1;113(9):2484-9. doi: 10.1073/pnas.1518934113. Epub 2016 Feb 16.

9.

Advances in experimental systems to study hepatitis C virus in vitro and in vivo.

Catanese MT, Dorner M.

Virology. 2015 May;479-480:221-33. doi: 10.1016/j.virol.2015.03.014. Epub 2015 Apr 4. Review.

10.

Hepatitis C virus RNA functionally sequesters miR-122.

Luna JM, Scheel TK, Danino T, Shaw KS, Mele A, Fak JJ, Nishiuchi E, Takacs CN, Catanese MT, de Jong YP, Jacobson IM, Rice CM, Darnell RB.

Cell. 2015 Mar 12;160(6):1099-110. doi: 10.1016/j.cell.2015.02.025.

11.

Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.

Bankwitz D, Vieyres G, Hueging K, Bitzegeio J, Doepke M, Chhatwal P, Haid S, Catanese MT, Zeisel MB, Nicosia A, Baumert TF, Kaderali L, Pietschmann T.

J Virol. 2014 Nov;88(21):12644-55. doi: 10.1128/JVI.01145-14. Epub 2014 Aug 20.

12.

Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agents.

Vercauteren K, Van Den Eede N, Mesalam AA, Belouzard S, Catanese MT, Bankwitz D, Wong-Staal F, Cortese R, Dubuisson J, Rice CM, Pietschmann T, Leroux-Roels G, Nicosia A, Meuleman P.

Hepatology. 2014 Nov;60(5):1508-18. doi: 10.1002/hep.27196. Epub 2014 Jul 30.

13.

Completion of the entire hepatitis C virus life cycle in genetically humanized mice.

Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A.

Nature. 2013 Sep 12;501(7466):237-41. doi: 10.1038/nature12427. Epub 2013 Jul 31.

14.

Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmission.

Catanese MT, Loureiro J, Jones CT, Dorner M, von Hahn T, Rice CM.

J Virol. 2013 Aug;87(15):8282-93. doi: 10.1128/JVI.01102-13. Epub 2013 May 22.

15.

Ultrastructural analysis of hepatitis C virus particles.

Catanese MT, Uryu K, Kopp M, Edwards TJ, Andrus L, Rice WJ, Silvestry M, Kuhn RJ, Rice CM.

Proc Natl Acad Sci U S A. 2013 Jun 4;110(23):9505-10. doi: 10.1073/pnas.1307527110. Epub 2013 May 20.

16.

Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells.

Andrus L, Marukian S, Jones CT, Catanese MT, Sheahan TP, Schoggins JW, Barry WT, Dustin LB, Trehan K, Ploss A, Bhatia SN, Rice CM.

Hepatology. 2011 Dec;54(6):1901-12. doi: 10.1002/hep.24557.

17.

A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.

Meuleman P, Catanese MT, Verhoye L, Desombere I, Farhoudi A, Jones CT, Sheahan T, Grzyb K, Cortese R, Rice CM, Leroux-Roels G, Nicosia A.

Hepatology. 2012 Feb;55(2):364-72. doi: 10.1002/hep.24692. Epub 2011 Dec 16.

18.

A genetically humanized mouse model for hepatitis C virus infection.

Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A.

Nature. 2011 Jun 8;474(7350):208-11. doi: 10.1038/nature10168.

19.

Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system.

Jones CT, Catanese MT, Law LM, Khetani SR, Syder AJ, Ploss A, Oh TS, Schoggins JW, MacDonald MR, Bhatia SN, Rice CM.

Nat Biotechnol. 2010 Feb;28(2):167-71. doi: 10.1038/nbt.1604. Epub 2010 Jan 31.

20.

Role of scavenger receptor class B type I in hepatitis C virus entry: kinetics and molecular determinants.

Catanese MT, Ansuini H, Graziani R, Huby T, Moreau M, Ball JK, Paonessa G, Rice CM, Cortese R, Vitelli A, Nicosia A.

J Virol. 2010 Jan;84(1):34-43. doi: 10.1128/JVI.02199-08.

21.

High-avidity monoclonal antibodies against the human scavenger class B type I receptor efficiently block hepatitis C virus infection in the presence of high-density lipoprotein.

Catanese MT, Graziani R, von Hahn T, Moreau M, Huby T, Paonessa G, Santini C, Luzzago A, Rice CM, Cortese R, Vitelli A, Nicosia A.

J Virol. 2007 Aug;81(15):8063-71. Epub 2007 May 16.

22.

AROS-29 is involved in adaptive response to oxidative stress.

Montesano Gesualdi N, Chirico G, Catanese MT, Pirozzi G, Esposito F.

Free Radic Res. 2006 May;40(5):467-76.

PMID:
16551573

Supplemental Content

Loading ...
Support Center